1-Hour Program

See Credit Details Below

Overview

The life sciences industry continues to be a key target for securities fraud litigation and there is no indication that this trend will reverse any time soon.  As a result, life sciences companies must have a firm grasp on the recent developments in this area of the law, including the nature of the claims being brought, how courts throughout the country are reacting to various types of claims, and best practices firms can employ to avoid securities fraud litigation.  This analysis is particularly helpful with an overall backdrop of the current state of securities fraud litigation both domestically and globally. 

Please join David H. Kistenbroker, Esq. and Joni S. Jacobsen, Esq. of Dechert LLP as they address: 

  • The dramatic increase in securities fraud cases in 2017, including against life science companies, and how to assess the risk of being subject to such litigation
  • The globalization of securities fraud litigation and how that relates to and impacts domestic claims
  • Trends in the types of securities fraud cases being filed and how they relate to the life cycle of the approval process
  • Courts’ reaction to the increased filings and analysis regarding which types of claims are more likely to survive a motion to dismiss
  • Best practices firms can employ to minimize the risk of securities fraud litigation

 

Program Level:  Update 

Intended Audience:  In-house counsel, board members, outside attorneys, corporate officers, and other allied professionals responsible for the preparation of public reporting and disclosure documents relating to companies in the life sciences industry 

Prerequisites:  A familiarization with the preparation of public reporting and disclosure documents, particularly with respect to companies in the life sciences industry   

Advanced Preparation:  None 

Credit Details